Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?

被引:0
|
作者
Bisson, William H. [1 ]
机构
[1] Oregon State Univ, Environm Hlth Sci Ctr, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA
关键词
Chemical Genomics; Clinical Phase; Drug; High Throughput Screening; Repurposing; Translational Research; Virtual Ligand Screening; ABANDONED DRUGS; DISCOVERY; CANCER;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
More needs to be done by the private sector to optimize the drug discovery and development pipeline. In addition, significant efforts should also be focused on the understanding of mechanism of diseases, on the characterization of unexplored biochemical pathways and on the validation of new protein targets. Chemical genomics, which uses chemical probes to help understand the complexity of biological systems at the gene and protein levels, has proven in recent years to be an important tool. Experimental and computational chemical genomic screenings have been used by the private sector and recently also by academia and non-profit institutions for drug repurposing or repositioning to find new indications for known drugs. A detailed overview of the current initiatives in drug repurposing, initiated by the major governmental funding agencies around the world is reported. The push towards greater efficiency is encouraging drug repurposing and other techniques in chemical genomics. Finding the best ways to improve translational research and accelerate the regulation of clinical phases means being able to launch safer drugs into the market faster.
引用
收藏
页码:1883 / 1888
页数:6
相关论文
共 50 条
  • [42] Pillar One and Alchemy: What Can We Learn from past Mistakes
    Moreno, Andres Baez
    Brauner, Yanv
    INTERTAX, 2023, 51 (12): : 811 - 821
  • [43] Cost and value in medical education - what we can learn from the past?
    Walsh, K.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2014, 44 (04): : 324 - 327
  • [44] COVID-19 and tourism: What can we learn from the past?
    Aronica, Martina
    Pizzuto, Pietro
    Sciortino, Caterina
    WORLD ECONOMY, 2022, 45 (02): : 430 - 444
  • [45] Making Medicine Precise and Personalized: What Can We Learn from the Past?
    Taylor, Anne L.
    CIRCULATION-HEART FAILURE, 2016, 9 (02) : 1 - 3
  • [46] Implementation of Industry 4.0 Technologies: What Can We Learn from the Past?
    Maghazei, Omid
    Netland, Torbjorn
    ADVANCES IN PRODUCTION MANAGEMENT SYSTEMS: THE PATH TO INTELLIGENT, COLLABORATIVE AND SUSTAINABLE MANUFACTURING, 2017, 513 : 135 - 142
  • [47] PREHOSPITAL EMERGENCY CARE IN HUNGARY: WHAT CAN WE LEARN FROM THE PAST?
    Gondocs, Zsigmond
    Olah, Andras
    Marton-Simora, Jozsef
    Nagy, Gabor
    Schaefer, Juergen
    Betlehem, Jozsef
    JOURNAL OF EMERGENCY MEDICINE, 2010, 39 (04): : 512 - 518
  • [48] COVID-19 and neurodegeneration: what can we learn from the past?
    Gatto, E. M.
    Fernandez Boccazzi, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (09) : E45 - E45
  • [49] OF WEEVILS AND WITCHES: WHAT CAN WE LEARN FROM THE GHOST OF RESPONSIBILITY PAST?
    Ferzan, Kimberly Kessler
    VIRGINIA LAW REVIEW, 2015, 101 (04) : 947 - 956
  • [50] Vaccines against neosporosis: What can we learn from the past studies?
    Monney, Thierry
    Hemphill, Andrew
    EXPERIMENTAL PARASITOLOGY, 2014, 140 : 52 - 70